Chirocaine Safety Comparison To Bupivacaine Must Await Resuscitation Data
Executive Summary
A safety comparison between Chiroscience/Zeneca's Chirocaine (levobupivacaine) and bupivacaine may depend on resuscitation data, FDA's Anesthetic & Life Support Drugs Advisory Committee members indicated Jan 12.
You may also be interested in...
Chiroscience Chirocaine Labeling Cites Possible Safety Advantage
Approved labeling for Chiroscience's long-acting local anesthetic Chirocaine (levobupivacaine) indicates a possible cardiac and central nervous system safety advantage over bupivacaine based on animal data.
Chiroscience Chirocaine Labeling Cites Possible Safety Advantage
Approved labeling for Chiroscience's long-acting local anesthetic Chirocaine (levobupivacaine) indicates a possible cardiac and central nervous system safety advantage over bupivacaine based on animal data.
Chirocaine Phase IV Commitments Include Dog Cardiac Resuscitation Study
Celltech Chiroscience Chirocaine (levobupivacaine) Phase IV commitments include the completion of a cardiovascular resuscitation study in dogs. Chirocaine, which cleared FDA August 5 with an indication for surgical anesthesia and pain management in adults, was deemed "approvable" in February.